Personalis is committed to addressing some of the most pressing needs in the liquid biopsy space.
TORONTO (PRWEB)
November 15, 2022
MRD is rapidly emerging as a key biomarker in therapy development and patient care, however, key challenges remain. Personalis is committed to addressing some of the most pressing needs in the liquid biopsy space.
In this webinar attendees will learn about the role of next-generation liquid biopsy assays in enabling: Earlier detection of disease recurrence; Utility in more disease indications, and at earlier stages of disease; Patient enrichment, screening/enrollment and surrogate endpoint analysis for clinical trials; Higher resolution variant tracking; And combining plasma and tissue analyses.
Register to learn how liquid biopsy assays go beyond recurrence detection in post-diagnosis cancer management.
Join Dan Norton, Associate Director, Product Management, Personalis Inc., for the live webinar on Friday, December 2, 2022, at 1pm EST (10am PST).
For more information, or to register for this event, visit Liquid Biopsy Assays: Beyond Recurrence Detection in Post-Diagnosis Cancer Management.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com
Share article on social media or email: